Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil

被引：32

作者：

Souza, L. K. H. ^{[1
,2
]}

Souza Junior, A. H. ^{[2
]}

Costa, C. R. ^{[1
]}

Faganello, J. ^{[3
]}

Vainstein, M. H. ^{[3
]}

Chagas, A. L. B.

Souza, A. C. M. ^{[1
]}

Silva, M. R. R. ^{[1
]}

机构：

[1] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil

[2] Univ Catolica Goias, Dept Biomed, Goiania, Go, Brazil

[3] Univ Fed Rio Grande do Sul, Ctr Biotecnol, BR-90046900 Porto Alegre, RS, Brazil

来源：

MYCOSES | 2010年 / 53卷 / 01期

关键词：

Cryptococcus neoformans; biotyping; serotyping; susceptibility; molecular typing; AIDS PATIENTS; VAR; NEOFORMANS; CITY; EPIDEMIOLOGY; SEROTYPE; STRAINS; DRUGS; DNA;

D O I：

10.1111/j.1439-0507.2008.01662.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P>A total of 124 Cryptococcus isolates, including 84 clinical strains obtained from cerebrospinal fluid from AIDS patients and 40 environmental isolates from pigeon excreta and from Eucalyptus trees, were studied. The varieties, serotypes, phospholipase activity and molecular profile of these isolates were determined. Cryptococcus neoformans var. grubii serotype A was identified in 120 isolates and Cryptococcus gattii serotype B in four isolates. The clinical isolates showed higher phospholipase activity than environmental isolates. Similar patterns of in vitro susceptibility to amphotericin B, fluconazole, itraconazole and voriconazole and no resistance were found for all isolates. Molecular type VNI (C. neoformans var. grubii) was recovered in 80 clinical and 40 environmental isolates while the type VGIII (C. gattii) was found in four clinical isolates. This study demonstrated for the first time the molecular types of clinical and environmental Cryptococcus isolates in the midwest Brazil region.

引用

页码：62 / 67

页数：6

共 33 条

[21]

2-2

[22]

Meyer W, 2003, EMERG INFECT DIS, V9, P189

[23]

*MIN SAUD BRAS, 2002, DAD PESQ DST AIDS CO

[24] Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques [J].

Moraes, EMP ;

Prímola, NS ;

Hamdan, JS .

MYCOSES, 2003, 46 (5-6) :164-168

[25] DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples [J].

Morera-López, Y ;

Torres-Rodríguez, JM ;

Jiménez-Cabello, T ;

Baró-Tomás, T ;

Alía-Aponte, C ;

Lázera, MS .

MYCOPATHOLOGIA, 2005, 160 (01) :9-14

[26] Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil:: Analysis of host and regional patterns [J].

Nishikawa, MM ;

Lazera, MS ;

Barbosa, GG ;

Trilles, L ;

Balassiano, BR ;

Macedo, RCL ;

Bezerra, CCF ;

Pérez, MA ;

Cardarelli, P ;

Wanke, B .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (01) :73-77

[27]

OLIVEIRA MTB, 2004, J CLIN MICROBIOL, V42, P1356

[28]

PRICE MF, 1982, SABOURAUDIA, V20, P7

[29] Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model [J].

Santangelo, R ;

Zoellner, H ;

Sorrell, T ;

Wilson, C ;

Donald, C ;

Djordjevic, J ;

Shounan, Y ;

Wright, L .

INFECTION AND IMMUNITY, 2004, 72 (04) :2229-2239

[30]

Soares Maria Cecília Bianchi, 2005, Rev. Inst. Med. trop. S. Paulo, V47, P31, DOI 10.1590/S0036-46652005000100006

← 1 2 3 4 →